Scarica l'app Stockscreener
1.7848
1.42%
0.0248
Precedente Chiudi:
$1.76
Aprire:
$1.77
Volume 24 ore:
500.58K
Relative Volume:
0.17
Capitalizzazione di mercato:
$107.67M
Reddito:
-
Utile/perdita netta:
$-27.37M
Rapporto P/E:
-3.9209
EPS:
-0.4552
Flusso di cassa netto:
$-25.99M
1 W Prestazione:
+3.78%
1M Prestazione:
+6.25%
6M Prestazione:
-66.38%
1 anno Prestazione:
-40.89%
Intervallo 1D:
$1.745
$1.84
Intervallo di 1 settimana:
$1.65
$1.84
Portata 52W:
$1.07
$6.175
Aldeyra Therapeutics Inc Stock (ALDX) Company Profile
Nome
Aldeyra Therapeutics Inc
Settore
Industria
Telefono
781-761-4904
Indirizzo
131 HARTWELL AVENUE, LEXINGTON, MA
Compare ALDX vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALDX
Aldeyra Therapeutics Inc
|
1.785 | 106.17M | 0 | -27.37M | -25.99M | -0.4552 |
VRTX
Vertex Pharmaceuticals Inc
|
449.32 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
613.56 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.10 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
279.25 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.83 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Aldeyra Therapeutics Inc Stock (ALDX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-18 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-04-03 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2024-04-02 | Ripresa | H.C. Wainwright | Buy |
| 2022-04-27 | Ripresa | H.C. Wainwright | Buy |
| 2021-02-08 | Iniziato | H.C. Wainwright | Buy |
| 2020-12-16 | Iniziato | Berenberg | Buy |
| 2020-10-30 | Iniziato | Jefferies | Buy |
| 2020-10-16 | Iniziato | BTIG Research | Buy |
| 2020-09-22 | Iniziato | Alliance Global Partners | Buy |
| 2020-05-12 | Iniziato | Oppenheimer | Outperform |
| 2018-12-04 | Iniziato | Citigroup | Buy |
| 2018-09-26 | Reiterato | Cantor Fitzgerald | Overweight |
| 2018-09-13 | Iniziato | Janney | Buy |
| 2018-01-26 | Iniziato | Seaport Global Securities | Buy |
| 2016-09-26 | Iniziato | H.C. Wainwright | Buy |
| 2016-07-01 | Iniziato | Stifel | Buy |
| 2015-07-01 | Iniziato | Canaccord Genuity | Buy |
| 2015-03-25 | Iniziato | Chardan Capital Markets | Buy |
| 2015-03-20 | Reiterato | H.C. Wainwright | Buy |
| 2014-11-18 | Iniziato | H.C. Wainwright | Buy |
| 2014-06-19 | Iniziato | Aegis Capital | Buy |
Mostra tutto
Aldeyra Therapeutics Inc Borsa (ALDX) Ultime notizie
Bronstein, Gewirtz & Grossman, LLC Is Investigating Aldeyra Therapeutics, Inc. (ALDX) And Encourages Stockholders to Connect - ACCESS Newswire
Aldeyra appoints Darlene Deptula-Hicks to board of directors By Investing.com - Investing.com Nigeria
Aldeyra Therapeutics (ALDX) grants director options on 73,318 shares - Stock Titan
Aldeyra Therapeutics (ALDX) director receives three new stock option grants - Stock Titan
Aldeyra Therapeutics (ALDX) director receives new stock option awards - Stock Titan
Aldeyra Therapeutics (ALDX) grants board member new stock option awards - Stock Titan
[Form 4] Aldeyra Therapeutics, Inc. Insider Trading Activity - Stock Titan
Aldeyra (ALDX) director granted multiple new stock option awards - Stock Titan
Aldeyra Therapeutics (ALDX) director receives long-dated stock option awards - Stock Titan
Aldeyra Therapeutics (ALDX) director Deptula-Hicks submits initial Form 3 - Stock Titan
Aldeyra Therapeutics, Inc. (ALDX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Aldeyra Therapeutics Adds Independent Director, Affirms Governance Support - The Globe and Mail
Aldeyra Therapeutics CEO, President & Director Acquires 18% More Stock - simplywall.st
CEO, President & Director of Aldeyra Therapeutics Picks Up 18% More Stock - Yahoo Finance
Darlene Deptula-Hicks joins Aldeyra (ALDX) board as audit committee chair - Stock Titan
Aldeyra Therapeutics Appoints Darlene Deptula-Hicks to Board of Directors - BioSpace
What Does Darlene Deptula-Hicks Bring to Aldeyra's Board - Kavout
Aldeyra appoints Darlene Deptula-Hicks to board of directors - Investing.com
Aldeyra Therapeutics eyes FDA feedback as dry eye drug faces make-or-break moment - MSN
Why Did ALDX Stock Tank 70% Today? - Stocktwits
Todd Brady Increases Stake in Aldeyra Therapeutics Inc with Sign - GuruFocus
Todd Brady Increases Stake in Aldeyra Therapeutics Inc with Significant Share Purchase - GuruFocus
Aldeyra Therapeutics CEO Todd Brady buys $418,450 in stock By Investing.com - Investing.com Australia
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Aldeyra Therapeutics CEO Todd Brady buys $418,450 in stock - Investing.com
Aldeyra Therapeutics Insider Bought Shares Worth $418,450, According to a Recent SEC Filing - marketscreener.com
Aldeyra (NASDAQ: ALDX) CEO Todd Brady purchases 250,000 common shares - Stock Titan
3 Promising Penny Stocks With Market Caps Reaching $300M - Sahm
Aldeyra Therapeutics Eyes FDA Feedback as Dry Eye Drug Faces Make-or-Break Moment - inkl
ALDX: Late-stage dry eye program nears key FDA decision, with strong cash and AbbVie partnership - TradingView
Aldeyra Therapeutics Q1 2026 Earnings: Narrower Loss Beats Estimates as Pipeline AdvancesCore Business Growth - newsline.com
Aldeyra Therapeutics CEO to Speak at Jefferies Global Healthcare Conference - GuruFocus
Aldeyra Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference - Business Wire
ALDX Technical Analysis | Trend, Signals & Chart Patterns | ALDEYRA THERAPEUTICS INC (NASDAQ:ALDX) - ChartMill
ALDX Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost Discipline Amid Pipeline ProgressEPS Surprise History - newsline.com
Lawsuit filed for Investors who lost money with shares of Zoetis Inc. (NYSE: ZTS) - openPR.com
ANGI Investors Have Opportunity to Join Angi Inc. Fraud Investigation with the Schall Law Firm - Business Wire
Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) Investor Alert: Deadline in Lawsuit on May 29, 2026 - openPR.com
Gossamer Bio, Inc. (NASDAQ: GOSS) Investor Alert: Deadline in Lawsuit on June 1, 2026 - openPR.com
Aldeyra Therapeutics Faces Class Action Deadline Amid FDA Rejections (ALDX) - GuruFocus
ALDX FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Aldeyra - GuruFocus
ALDX DEADLINEFINAL REMINDER: Bronstein, Gewirtz & Grossman LLC Alerts Aldeyra Therapeutics, Inc. Investors to Participate in the Class Action Lawsuit Today - ACCESS Newswire
Aldeyra Therapeutics Faces Securities Fraud Lawsuit Amid FDA Rej - GuruFocus
ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Business Wire
ALDX FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Aldeyra Therapeutics (ALDX) Investors of Securities Class Action Deadline on May 29, 2026 - 巴士的報
ALDX UPCOMING DEADLINE : The Gross Law Firm Alerts Aldeyra - GlobeNewswire
Aldeyra Therapeutics Inc Azioni (ALDX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.40%
0.80%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):